Key result
First-trimester in utero SSRI exposure increased the risk of mild nonsyndromic congenital heart defects compared to unexposed newborns (3.40% vs 1.60%; RR 2.17, 95% CI 1.07-4.39).
Why the study?
Does first-trimester maternal use of SSRIs increase the risk of nonsyndromic congenital heart defects in newborns?
Population
67,871 newborns born at a single tertiary center between 2000 and 2007, including 235 exposed to…
Comparison
First-trimester maternal use of selective… vs No first-trimester maternal use of SSRIs.
Design
Cohort
Follow-up
Day 2 or 3 of life
Authors
Loading...
May inform first-trimester SSRI counseling; leaves open causality and requires confirmation in larger prospective studies.
Cohort (n=67,871)
No
Does first-trimester maternal use of SSRIs increase the risk of nonsyndromic congenital heart defects in newborns?
Relative Risk: 2.17 (95% CI 1.07–4.39)
Absolute Event Rate: 3.4% vs 1.6%
First-trimester maternal SSRI use is associated with a twofold increased relative risk of mild nonsyndromic congenital heart defects in newborns, though the absolute risk remains low.
Merlob et al. (2009) conducted a cohort in In utero SSRI exposure (n=67,871). Selective serotonin reuptake inhibitors (SSRIs) vs. Unexposed newborns was evaluated on Nonsyndromic congenital heart defects (RR 2.17, 95% CI 1.07-4.39). First-trimester in utero SSRI exposure increased the risk of mild nonsyndromic congenital heart defects compared to unexposed newborns (3.40% vs 1.60%; RR 2.17, 95% CI 1.07-4.39).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: